| CCERX | FXAIX | CCERX / FXAIX | |
| Total Expense Ratio | 1.08 | 0.01 | 7,200% |
| Annual Report Gross Expense Ratio | 1.46 | 0.01 | 9,733% |
| Fund Existence | 20 years | 15 years | - |
| Gain YTD | 11.405 | 17.153 | 66% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 476M | 739B | 0% |
| Annual Yield % from dividends | 0.46 | 1.11 | 41% |
| Returns for 1 year | 0.32 | 14.07 | 2% |
| Returns for 3 years | 38.25 | 74.61 | 51% |
| Returns for 5 years | 19.07 | 99.82 | 19% |
| Returns for 10 years | 49.94 | 258.16 | 19% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GDXD | 10.87 | 0.42 | +4.02% |
| MicroSectors™ Gold Mns 3X Inv Lvrgd ETN | |||
| EOS | 23.04 | 0.28 | +1.23% |
| Eaton Vance Enhance Equity Income Fund II | |||
| IBGA | 25.01 | 0.03 | +0.10% |
| iShares iBonds Dec 2044 Term Trsy ETF | |||
| EOT | 16.52 | -0.01 | -0.06% |
| EATON VANCE NATIONAL Municipal OPPORTUNITIES TRUST | |||
| LFSC | 36.62 | -0.61 | -1.64% |
| F/m Emerald Life Sciences Innovation ETF | |||